Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
Titel:
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
Auteur:
Rha, Sun Young Oh, Do-Youn Yañez, Patricio Bai, Yuxian Ryu, Min-Hee Lee, Jeeyun Rivera, Fernando Alves, Gustavo Vasconcelos Garrido, Marcelo Shiu, Kai-Keen Fernández, Manuel González Li, Jin Lowery, Maeve A Çil, Timuçin Cruz, Felipe Melo Qin, Shukui Luo, Suxia Pan, Hongming Wainberg, Zev A Yin, Lina Bordia, Sonal Bhagia, Pooja Wyrwicz, Lucjan S